Cardiff Oncology is a biotechnology business based in the US. Cardiff Oncology shares (CRDF) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.68 – a decrease of 3.6% over the previous week. Cardiff Oncology employs 32 staff and has a trailing 12-month revenue of around $683,000.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.68 |
|---|---|
| 52-week range | $2.01 - $5.64 |
| 50-day moving average | $3.40 |
| 200-day moving average | $3.14 |
| Wall St. target price | $13.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.95 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.82 from 2025-05-02
| 1 week (2025-04-28) | -4.41% |
|---|---|
| 1 month (2025-04-04) | 2.55% |
| 3 months (2025-02-06) | -38.96% |
| 6 months (2024-11-06) | -25.98% |
| 1 year (2024-05-06) | -18.50% |
|---|---|
| 2 years (2023-05-05) | 50.00% |
| 3 years (2022-05-05) | 110.45% |
| 5 years (2020-05-05) | 123.81% |
| Revenue TTM | $683,000 |
|---|---|
| Gross profit TTM | $-36,169,000 |
| Return on assets TTM | -34.01% |
| Return on equity TTM | -59.51% |
| Profit margin | 0% |
| Book value | $1.25 |
| Market Capitalization | $187.6 million |
TTM: trailing 12 months
We're not expecting Cardiff Oncology to pay a dividend over the next 12 months.
Cardiff Oncology's shares were split on a 1:6 basis on 19 February 2019 . So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiff Oncology shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cardiff Oncology shares which in turn could have impacted Cardiff Oncology's share price.
Over the last 12 months, Cardiff Oncology's shares have ranged in value from as little as $2.01 up to $5.6395. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiff Oncology's is 1.734. This would suggest that Cardiff Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .